Supplementary Methods from Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Year: 2023
Type: supplementary-materials
Authors: Anita Kulukian, Patrice Lee, Janelle Taylor, Robert Rosler, Peter de Vries, Daniel Watson, Andres Forero-Torres, Scott Peterson
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362490968